During the second and final day of a drug pricing hearing, Democratic members of the House Oversight and Reform Committee again pounded pharma CEOs, accusing them of taking unjustified price increases
The House Committee on Oversight and Reform Wednesday released reports and documents that, according to committee Democrats, demonstrate that drug companies take unjustified price increases and engage
The introduction of generic competition in the U.S. for MS blockbuster Tecfidera, which accounted for 40% of Biogen’s product revenue last half, puts increased pressure on the remainder of big